Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.48 |
| ▸ | CDK2 | P24941 | 5/20 | 0.48 |
| ▸ | CDK1 | P06493 | 2/20 | 0.48 |
| ▸ | CDK4 | P11802 | 2/20 | 0.48 |
| ▸ | CCNE2 | O96020 | 4/20 | 0.46 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.46 |
| ▸ | CCND1 | P24385 | 1/20 | 0.46 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16086080 | 0.82 | ALOX15 (0.54) | ALOX15FFAR2MAPTMEN1KMT2A | |
| SCHEMBL28089066 | 0.81 | FFAR2 (0.50) | ALOX15FFAR2LIMK1MAPTMEN1 | |
| SCHEMBL27545748 | 0.81 | ALOX15 (0.53) | ALOX15FFAR2MAPTMEN1KMT2A | |
| SCHEMBL12545447 | 0.80 | CCNE1 (0.66) | ALOX15FFAR2LIMK1MAPTMEN1 | |
| SCHEMBL6279225 | 0.80 | FFAR2 (0.49) | ALOX15FFAR2 | |
| SCHEMBL24072541 | 0.80 | ALOX15 (0.52) | ALOX15FFAR2LMNALIMK1MAPT | |
| SCHEMBL30142794 | 0.80 | ALOX15 (0.52) | ALOX15FFAR2LMNALIMK1MAPT | |
| SCHEMBL1503875 | 0.79 | FFAR2 (0.48) | ALOX15FFAR2MAPTMEN1KMT2A | |
| SCHEMBL2175131 | 0.78 | RAB9A (0.60) | LMNAMAPTMEN1KMT2ACCNE1 | |
| SCHEMBL5837008 | 0.78 | SMN1; SMN2 (0.56) | ALOX15FFAR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2024349-B1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-2373634-B1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARM CO LTD (JP) | 2015-11-11 | — | — | EP | disclosed |
| US-20150231141-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC (US) | 2015-08-20 | — | — | US | disclosed |
| US-9006275-B2 | Compounds as cannabinoid receptor ligands and uses thereof | ABBVIE INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-8841334-B2 | Compounds as cannabinoid receptor ligands and uses thereof | ABBVIE INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8546583-B2 | Pain, inflammatory or immune disorders, neurological disorders, cancers of the immune system, respiratory disorders, cardiovascular disorders, neuroprotection; e.g. 5-chloro-N-[(2Z)-5-(1-hydroxy-1-methylethyl)-3-[((cis)-3-methoxycyclobutyl)methyl]-4-methyl-1,3-thiazol-2(3H)-ylidene]-2-methoxybenzamide | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2222165-B1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-2444397-A1 | Heteroaryl-ureas and their use as glucokinase activators | Novo Nordisk A/S (DK) | 2012-04-25 | — | — | EP | disclosed |
| US-20110086855-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-04-14 | — | — | US | disclosed |
| US-7875639-B2 | Compounds as cannabinoid receptor ligands and uses thereof | ABBOTT LABORATORIES (US) | 2011-01-25 | — | — | US | disclosed |
| EP-2038266-A2 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | Abbott Laboratories (US) | 2009-03-25 | — | — | EP | disclosed |
| EP-2024349-A2 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | Abbott Laboratories (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20080064699-A1 | Such as N-[3-(2-methoxyethyl)-1,3-thiazol-2(3H)-ylidene]adamantane-1-carboxamide; neuropathic, nociceptive and/or inflammatory pain; neuroprotection | ABBVIE INC. | 2008-03-13 | — | — | US | disclosed |
| US-20080058335-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC. | 2008-03-06 | — | — | US | disclosed |
| WO-2007140439-A2 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007140385-A2 | THIAZOLE COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2007-12-06 | — | — | WO | disclosed |
| EP-0412404-B1 | Thiazole derivatives, processes for production thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-01-31 | — | — | EP | disclosed |
| US-5369107-A | Thiazole derivatives, processes for production thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-29 | — | — | US | disclosed |
| US-5256675-A | Antirheumatic agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-10-26 | — | — | US | disclosed |
| EP-0412404-A2 | Thiazole derivatives, processes for production thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150231141-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, OPRL1 | ALOX15 1480/4885FFAR2 65/4885LMNA 3363/4885 |
| US-20110086855-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, OPRL1 | ALOX15 1480/4885FFAR2 65/4885LMNA 3363/4885 |
| US-20080064699-A1 | Such as N-[3-(2-methoxyethyl)-1,3-thiazol-2(3H)-ylidene]adamantane-1-carboxamide; neuropathic, nociceptive and/or inflammatory pain; neuroprotection | OPRL1, OPRK1, OPRD1 | ALOX15 1043/4885FFAR2 412/4885LMNA 1664/4885 |
| US-20080058335-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, OPRL1 | ALOX15 1594/4885FFAR2 164/4885LMNA 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.